Protagonist Q2 net loss $30.6M; cash $595.4M; JNJ-2113 Phase 3 data expected Q4 2024

Protagonist Therapeutics, Inc

2024-Q2 EPS reported $2.77 revenue$259,120,000

Q2 net loss of $30.6M ($0.50/share) vs $38.5M loss in Q2 2023; six-month net income $176.7M from Takeda upfront.
Cash, equivalents and marketable securities of $595.4M as of June 30, 2024; runway through end of 2027.
JNJ-2113 Phase 3 ICONIC-LEAD and ICONIC-TOTAL in psoriasis primary endpoint completion expected Q4 2024.
Phase 2b ANTHEM in ulcerative colitis primary endpoint completion also expected Q4 2024; Phase 3 VERIFY rusfertide topline due Q1 2025.
Dr. Newman Yeilding appointed Chief Scientific Advisor effective August 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.